Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several top-sellers. At the end of 2023, Pfizer completed its acquisition of Seagen Inc. (NASDAQ: SGEN), a biotechnology leader in transformative cancer medicines. Although Pfizer still has a few growth best-sellers, migraine therapy Nurtec and respiratory syncytial virus (RSV) vaccine, Pfizer is betting on such
Newsweek covers new research out of France into links between common food additives found in U.S. ultra-processed foods and certain forms of cancer. Also in the news, Johnson & Johnson's blood cancer therapy gets FDA approval; Iowa has fastest-growing rate of new cancer in the U.S.; and more.
Prothena Announces Appointment of Daniel G Welch as Director and Chair Designate lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Shares of Seagen Inc. (NASDAQ:SGEN – Get Free Report) have received a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price […]